鄰近類別 期刊論文 [19/20] 類別統計 近3年內發表的文件:0(0.00%) 含全文筆數:7(63.64%) 文件下載次數統計 下載大於0次:7(100.00%) 下載大於100次:7(100.00%) 檔案下載總次數:4553(19.25%) 最後更新時間: 2024-12-03 10:22 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Phase I study of biweekly liposome ... Phase I dose-escalation study of so... Activation of Akt/FoxO axis confers... Concurrent chemoradiotherapy with c... Concurrent chemoradiotherapy with c... Early data from a phase I study of ... Randomized, phase 1 study of everol... Randomized, phase I, and pharmacoki... Induction of cell death by a novel ... D-501036, a novel selenophene-base ...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目1-11 / 11. (共1頁) 1  每頁顯示[10|25|50]項目

日期	題名	關聯
2016-02	Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors	Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 745.
2013-05	Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma	Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number 10619.
2012-09	Early data from a phase I study of nintedanib (BIBF1120) in Asian patients with advanced hepatocellular carcinoma	Annals of Oncology. 2012 Sep;23(Suppl. 9):246-247.
2012-02	Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on firstline oxaliplatin-based chemotherapy	Journal of Clinical Oncology. 2012 Feb;30(4):613.
2011-04	Activation of Akt/FoxO axis confers resistance to cisplatin in human nasopharyngeal carcinomas	Cancer Research. 2011 Apr;71:Abstract number 1701.
2011-02	Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma	Journal of Clinical Oncology. 2011 Feb;29(Suppl. 4):Abstract Number 79.
2010-06	Randomized, phase 1 study of everolimus in patients with advanced hepatocellular carcinoma	Annals of Oncology. 2010 Jun;21(Suppl. 6):27.
2009-09	Synergistic augmentation of arsenic trioxide-induced cytotoxicity by BCNU through reactive oxygen species-related autophagic pathway in human solid tumors	EJC Supplements. 2009 Sep;7(3):16.
2009-05-20	Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)	Journal of Clinical Oncology. 2009 May 20;27(15s):Abstract number 4587.
2006-11	D-501036, a novel selenophene-base triheterocycle derivative exhibits potent in vitro and in vivo anti-tumoral activity, which involves DNA-damage and ATM activation	EJC Supplements. 2006 Nov;4(12):92.
2005-12	Induction of cell death by a novel selenophene derivative, D-501036, in human cancer cell lines	Clinical Cancer Research. 2005 Dec;11(24):9101S.

顯示項目1-11 / 11. (共1頁) 1  每頁顯示[10|25|50]項目